purpos
field
vaccinolog
evolv
last
year
first
viral
vector
hiv
gene
insert
construct
vaccin
regimen
use
myriad
strategi
strategi
includ
germlinetarget
lineagebas
structureguid
immunogen
design
narr
review
outlin
histor
context
hiv
vaccinolog
subsequ
highlight
scientif
discoveri
last
year
promis
propel
field
forward
method
conduct
search
electron
databas
pubm
embas
experiment
studi
involv
new
hiv
immunogen
design
titl
abstract
review
public
exclud
written
languag
english
andor
letter
editor
commentari
conferenceonli
present
use
clinicaltrialsgov
identifi
complet
ongo
clinic
trial
use
strategi
find
hiv
vaccinolog
field
undergon
period
signific
growth
last
decad
find
elucid
preclin
studi
reveal
import
interact
cellular
humor
immun
system
result
sever
new
ration
design
vaccin
strategi
develop
explor
last
year
includ
nativelik
envelop
trimer
nanoparticl
mrna
vaccin
design
strategi
among
other
sever
strategi
shown
enough
promis
anim
model
progress
toward
firstinhuman
phase
clinic
trial
implic
rapid
develop
preclin
earlyphas
clinic
studi
suggest
toler
effect
hiv
vaccin
may
horizon
clin
ther
xxxx
xxx
xxx
despit
decad
research
toler
effect
vaccin
still
unavail
barrier
achiev
goal
includ
overcom
envelop
env
sequenc
divers
rapidli
elicit
protect
broadli
neutral
antibodi
bnab
nonneutr
humor
cellular
respons
earli
year
hiv
vaccinolog
vaccin
develop
proceed
along
tradit
pathway
focus
humor
arm
immun
system
success
prevent
vaccin
use
antibodi
bind
function
correl
protect
fact
classic
approach
isol
inactiv
inject
whole
partial
microorgan
caus
diseas
success
use
sinc
approach
initi
attempt
exampl
mous
studi
use
formaldehydeinactiv
virion
promis
subsequ
analysi
found
result
artifact
attenu
serious
consid
vaccin
candid
longterm
result
natur
occur
attenu
infect
nef
delet
strain
infect
sydney
blood
bank
cohort
produc
evid
immunolog
damag
concert
effort
vaccin
test
undertaken
aid
vaccin
evalu
group
pediatr
aid
clinic
trial
group
consortia
along
sever
group
conduct
earlyphas
vaccin
studi
use
recombin
subunit
protein
immunogen
result
trial
gener
discourag
suggest
toler
efficaci
regardless
immunogen
proceed
toward
efficaci
trial
earli
earli
result
earliest
efficaci
trial
becam
avail
particular
san
franciscoebas
vaxgen
inc
complet
phase
iib
iii
trial
men
sex
men
women
intraven
drug
user
studi
assess
proteinbas
vaccin
aidsvax
contain
protein
variou
subtyp
result
disappoint
infect
rate
vaccin
group
compar
placebo
group
demonstr
efficaci
neither
signific
effect
viral
load
tlymphocyt
cell
count
person
becom
infect
despit
discourag
result
pressur
advanc
vaccin
scienc
includ
establish
dale
betti
bumper
vaccin
research
center
vrc
nation
institut
health
bethesda
maryland
program
incentiv
commerci
vaccin
develop
polit
environ
decis
made
undertak
phase
iii
efficaci
trial
design
reassess
aidsvax
heterolog
primeboost
strategi
trial
involv
prime
immun
system
canarypoxbas
vector
contain
genet
engin
version
env
gag
pol
gene
alvac
boost
alvac
alumadjuv
protein
vaccin
aidsvax
trial
highli
controversi
multipl
earlyphas
clinic
trial
reveal
compon
poorli
immunogen
given
isol
propon
argu
trial
provid
opportun
test
feasibl
primeboost
design
test
cellular
immun
correl
protect
wherea
oppon
emphas
excess
cost
trial
high
likelihood
failur
use
immunogen
previous
induc
modest
tcell
humor
respons
evid
broad
viru
neutral
administ
alon
combin
littl
optim
strategi
would
succeed
earli
vaccin
candid
fail
elicit
broadli
protect
antibodi
respons
vaccin
field
shift
focu
vaccin
would
stimul
protect
tcell
respons
sever
anim
studi
suggest
vaccin
strategi
target
cellular
respons
might
success
prevent
infect
one
studi
simian
immunodefici
viru
siv
einfect
macaqu
suppress
siv
replic
experienc
increas
replic
cell
deplet
suggest
subset
cell
import
control
viral
replic
hivinfect
elit
control
provid
impetu
pursu
strategi
discov
impress
viral
control
associ
potent
broad
cellular
respons
work
gave
preclin
support
hiv
vaccin
trial
network
hvtn
ele
phase
iib
trial
step
hvtn
phambili
hvtn
design
stimul
cellular
respons
trial
healthi
adult
consid
high
risk
acquisit
immun
replicationdefici
human
adenoviru
serotyp
vector
clade
b
gene
insert
gag
pol
nef
interim
analysi
step
trial
reveal
higher
rate
transmiss
vaccin
group
compar
placebo
group
despit
evid
robust
humor
immun
respons
lead
earli
termin
trial
disappoint
field
fear
volunt
commun
post
hoc
analysi
found
subgroup
uncircumcis
male
person
preexist
neutral
antibodi
increas
infect
rate
two
year
later
report
trial
result
restor
sens
optim
regimen
modest
vaccin
efficaci
year
vaccin
vaccin
efficaci
high
first
year
howev
find
controversi
protect
occur
despit
lack
develop
neutral
antibodi
cytotox
tcell
respons
nonneutr
igg
antibodi
target
hiv
env
variabl
loop
identifi
correl
protect
wherea
high
level
envspecif
iga
antibodi
associ
lack
protect
high
cost
human
efficaci
trial
combin
unanticip
result
led
field
undertak
nuanc
studi
immunolog
respons
vaccin
infect
vaccine
extract
inform
otherwis
disappoint
studi
immunolog
studi
provid
clue
part
immun
respons
might
contribut
vaccinemedi
protect
exampl
siev
analysi
vaccin
recipi
identifi
portion
immun
respons
appear
place
pressur
viru
result
begun
drive
immunogen
design
sever
ongo
efficaci
trial
conduct
better
understand
result
trial
includ
hvtn
hvtn
studi
aim
enrol
particip
assess
toler
immun
respons
alvac
bival
subtyp
c
adjuv
clinicaltrialsgov
identifi
hvtn
studi
imbokodo
bloemfontein
south
africa
aim
assess
heterolog
prime
boost
regimen
use
clade
c
adjuv
aluminum
phosphat
clinicaltrialsgov
identifi
field
also
investig
viral
host
factor
contribut
format
bnab
humor
respons
neutral
multipl
clade
simultan
well
mechan
might
contribut
protect
alter
cours
infect
antivir
nonneutr
antibodi
work
result
isol
numer
bnab
person
live
vaccin
research
center
one
class
site
bnab
potent
neutral
known
isol
parallel
work
acut
infect
person
investig
isol
coevolv
bnab
isol
result
first
gener
germlinetarget
vaccin
design
base
structur
env
complex
bnab
potent
bnab
target
membraneproxim
extern
region
even
greater
neutral
breadth
recent
year
potent
nextgener
bnab
produc
neutral
breadth
high
virus
test
understand
allow
research
use
structur
conform
antibodi
target
antigen
guid
structurebas
immunogen
design
use
lineagebas
vaccin
design
target
unmut
common
ancestor
intermedi
antibodi
bnab
lineag
purpos
narr
review
describ
innov
vaccin
strategi
emerg
last
year
given
restrict
review
exhaust
instead
focus
immunogen
current
investig
human
studi
see
tabl
like
advanc
toward
inclus
phase
human
clinic
trial
near
futur
search
pubm
embas
use
term
hiv
vaccin
hiv
immun
human
vaccin
trial
sosip
vaccin
mrna
vaccin
protein
vaccin
peptid
vaccin
trimer
vaccin
aid
vaccin
immun
viral
vector
bnab
captur
proteinpeptid
mrna
vectorbas
hiv
vaccin
experiment
studi
passiv
immun
strategi
studi
publish
januari
januari
includ
narr
review
initi
electron
databas
search
identifi
remov
duplic
public
remain
studi
underw
titl
abstract
review
time
public
exclud
written
languag
english
andor
letter
editor
commentari
conferenceonli
present
although
qualiti
assess
studi
conduct
studi
includ
fulltext
review
studi
met
minimum
standard
technic
qualiti
observ
protocol
mandat
anim
welfar
act
use
clinicaltrialsgov
identifi
ongo
clinic
trial
use
strategi
complet
electron
databas
search
result
citat
list
refer
matur
cleav
env
spike
metast
glycoprotein
gp
heterotrim
surfac
protein
bind
receptor
transmembran
protein
involv
fusion
virion
host
cell
basi
coevolut
work
result
germlinetarget
vaccin
design
structur
recombinantli
produc
env
thought
critic
vaccin
design
display
bnab
epitop
conformationdepend
manner
may
stimul
bnab
unmut
common
ancestor
vaccin
success
prevent
infect
viru
high
antigen
divers
must
elicit
bnab
wide
neutral
breadth
andor
antibodi
mediat
antibodydepend
cellular
cytotox
effector
function
neutralizationresist
tier
virus
virus
high
resist
profil
variou
strategi
use
design
stabil
recombin
env
trimer
mimic
conform
nativ
env
trimer
one
approach
involv
stabil
interact
intermolecular
disulfid
bond
so
modifi
isoleucin
prolin
substitut
improv
trimer
sosip
research
design
nativelik
trimer
deriv
subtyp
transmittedfound
viru
isol
hivinfect
infant
autolog
neutral
antibodi
elicit
sosip
trimer
target
epitop
expos
hole
glycan
shield
current
unclear
whether
neutral
antibodi
elicit
manner
may
evolv
accommod
glycan
heterolog
env
develop
breadth
directli
elicit
sosip
immun
better
elucid
research
evalu
immunogen
sosip
glycan
hole
fill
immunogen
studi
use
solubl
trimer
found
success
bnab
product
neutral
autolog
tier
virus
rabbit
someth
previous
observ
envbas
immunogen
current
phase
clinic
trial
way
assess
toler
immunogen
healthi
particip
use
dose
escal
strategi
studi
expect
close
accrual
clinicaltrialsgov
identifi
past
year
variou
new
trimer
design
enhanc
antigen
thermost
develop
one
construct
call
singlechain
design
make
env
cleavageeindepend
replac
cleavag
site
glycineserin
linker
anoth
strategi
similar
singlechain
design
substitut
flexibl
glycin
serin
linker
g
cleavag
site
yield
cleavageindepend
env
mimic
call
nativ
flexibl
link
nfl
trimer
addit
interpromot
disulfid
bond
substitut
heptad
repeat
region
provid
improv
stabil
antigen
exposur
preclin
studi
rabbit
guinea
pig
nonhuman
primat
found
success
autolog
tier
neutral
respons
manufactur
concern
previous
limit
largescal
product
nfl
trimer
recent
studi
found
challeng
may
overcom
simplifi
largescal
product
platform
success
produc
homogen
nfl
trimer
use
chines
hamster
ovari
cell
line
nfl
singlechain
trimer
strategi
although
promis
often
result
fusion
intermedi
state
uncleav
trimer
address
improv
stabil
research
replac
cleavag
site
long
linker
result
uncleav
prefusionoptim
ufo
trimer
assum
nativelik
conform
similar
sosip
trimer
preclin
anim
model
nanoparticl
immunogen
success
induc
neutral
antibodi
activ
lowaffin
germlin
precursor
b
cell
activ
follicular
thelper
cell
nextgener
vaccin
immunogen
design
activ
select
rare
bcell
precursor
potenti
matur
bnab
strategi
call
germlin
target
develop
germlinetarget
immunogen
prime
bind
activ
precursor
b
cell
schief
et
al
scripp
center
hivaid
vaccin
immunolog
immunogen
discoveri
creat
engin
outer
domain
eod
env
bind
site
eod
simultan
abl
activ
select
germlinetarget
b
cell
guid
earli
somat
mutat
toward
matur
bnab
develop
team
ld
jone
et
al
xxxx
selfassembl
nanoparticl
display
copi
eod
effort
improv
bcell
activ
lymph
node
traffick
sixth
iter
germlinetarget
construct
success
activ
germlin
matur
b
cell
newer
variant
germlin
target
version
higher
affin
class
bcell
precursor
transgen
mous
model
almost
mice
abl
activ
bcell
precursor
produc
memori
respons
receiv
one
immun
use
subsequ
vitro
studi
human
sampl
abil
prime
human
bcell
repertoir
high
affin
b
cell
possibl
immunogen
could
drive
expuls
b
cell
germin
center
forc
matur
shortliv
plasma
cell
compart
occur
prime
b
cell
would
abl
reenter
germin
center
undergo
affin
matur
develop
neutral
breadth
previou
work
loweraffin
version
highlight
potenti
issu
loweraffin
immunogen
construct
result
develop
substanti
endogen
mous
bcell
respons
outcompet
ghl
cell
nanoparticl
current
evalu
phase
clinic
trial
sponsor
intern
aid
vaccin
initi
estim
close
accrual
clinicaltrialsgov
identifi
increas
consensu
homolog
primeboost
immun
may
effect
induc
bnab
protract
evolutionari
pathway
bnab
undergo
person
addit
bnab
characterist
suggest
success
vaccin
need
overcom
host
immunoregulatori
mechan
hinder
format
bnab
includ
limit
select
bcell
due
autoreact
host
antigen
bcell
lineag
vaccin
strategi
recreat
coevolutionari
event
env
humor
respons
prime
immun
system
earli
transmit
form
env
boost
sequenti
evolv
env
variant
drive
affin
matur
bnab
develop
select
rare
lineag
first
design
base
data
individu
coevolut
viru
site
bnab
lineag
observ
bnab
lineag
neutral
test
isol
lower
level
somat
hypermut
compar
bnab
lineag
make
attract
vaccin
target
initi
vaccin
strategi
use
env
protein
react
optim
step
lineag
tf
week
week
week
concept
current
evalu
studi
design
assess
toler
immunogen
vaccin
week
week
week
adjuv
glucopyranosyl
lipid
adjuv
formul
stabl
emuls
part
particip
randomli
assign
group
dose
escal
test
initi
immunogen
wherea
part
b
particip
randomli
assign
addit
sequenti
env
immun
strategi
studi
design
complement
similar
studi
previous
report
rabbit
expect
complet
accrual
clinicaltrialsgov
identifi
bcell
lineag
design
pursu
base
similar
data
bnab
lineag
studi
also
evalu
benefici
vaccin
outcom
reli
antibodi
function
exampl
trial
found
reduc
risk
infect
associ
antibodi
bound
env
region
neutral
antibodi
apex
antigen
env
region
mean
bnab
strategi
target
region
could
also
antibodydepend
cellular
cytotox
activ
addit
bnab
activ
evid
suggest
class
bnab
may
easier
elicit
preval
studi
person
class
protect
macaqu
challeng
chimer
simian
hiv
make
attract
vaccin
target
nucleic
acidebas
vaccin
particularli
use
mrna
continu
gener
signific
excit
technolog
advanc
recent
made
feasibl
vaccin
strategi
benefit
includ
lack
infecti
risk
abil
clinic
therapeut
modifi
immunogen
differ
formul
eas
manufactur
nake
mrna
vaccin
effect
extracellular
rnase
rapidli
degrad
genet
materi
howev
chemic
structur
modif
mrna
addit
carrier
molecul
includ
lipid
nanoparticl
lnp
protect
mrna
degrad
facilit
cellular
uptak
use
success
zika
viru
vaccin
develop
similar
mrnalnp
vaccin
design
elicit
potent
immun
respons
influenza
viru
anim
human
studi
one
preclin
studi
found
immun
human
mice
low
dose
mrnalnp
encod
bnab
yield
high
level
protect
antibodi
infect
group
later
found
singl
immun
low
dose
mrnalnp
vaccin
produc
strong
cell
particular
follicularhelp
cell
igg
respons
mice
rhesu
macaqu
follicularhelp
cell
respons
thought
critic
elicit
antigenspecif
durabl
bcell
respons
thu
vaccin
strategi
consid
particularli
promis
immun
selfamplifi
mrna
encod
clade
c
env
glycoprotein
anoth
mrnabas
vaccin
strategi
produc
potent
humor
cellular
immun
respons
anim
model
one
research
team
use
selfamplifi
mrna
vector
deliv
mosaic
highli
conserv
region
gag
pol
mous
model
result
suggest
method
could
induc
potent
durabl
tcell
respons
mice
prime
selfamplifi
mrna
vector
boost
viral
vector
modifi
vaccinia
viru
ankara
time
phase
clinic
trial
ongo
assess
mrna
vaccin
variou
infect
includ
zika
viru
cytomegaloviru
mrnabas
human
vaccin
trial
yet
start
dnabas
vaccin
first
develop
earli
experienc
resurg
excel
immunogen
anim
eas
manufactur
scalabl
storag
earli
studi
reveal
nake
dna
plasmid
vaccin
poorli
immunogen
human
howev
immunogen
improv
intraderm
deliveri
use
electropor
techniqu
appli
transient
electr
puls
cell
increas
permeabl
cell
membran
allow
nucleic
acid
enter
administr
conjunct
molecular
adjuv
interleukin
adjust
encourag
stimul
cellular
humor
arm
immun
system
hvtn
phase
trial
design
assess
effect
increas
dose
plasmid
dna
adjuv
conjunct
multiantigen
dna
vaccin
deliv
via
electropor
studi
found
combin
toler
result
increas
tcell
respons
decreas
respons
nonrepl
viral
vectorebas
vaccin
human
use
earli
viral
vector
vaccin
cellular
humor
immun
respons
vaccin
insert
inhibit
preexist
neutral
antibodi
vector
overcom
challeng
research
shift
vector
base
serotyp
lower
seropreval
chimer
form
adenoviru
prevent
immun
recognit
use
antigen
capsidincorpor
techniqu
chimpanzeeadenoviru
vector
human
previous
expos
antigen
capsideincorpor
strategi
chimer
creat
ad
polyhistidin
sequenc
capsid
protein
result
chimer
vector
fit
neutral
sera
suggest
abil
overcom
problem
preexist
immun
chimpanzeeadenoviru
vector
strategi
similarli
success
induc
antigenspecif
humor
cellular
immun
respons
variou
pathogen
includ
middl
east
respiratori
syndrom
coronaviru
lassa
fever
ebola
sever
phase
clinic
trial
use
chimpanzeeadenoviru
vector
deliv
vaccin
none
use
chimer
vector
date
although
live
attenu
viral
vaccin
success
induc
high
level
protect
antibodi
number
human
infect
includ
measl
ld
jone
et
al
smallpox
concern
toler
hinder
develop
live
attenu
vaccin
retain
pathogen
human
one
attract
altern
retain
benefit
replic
viral
vector
without
risk
infect
recombin
cytomegaloviru
cmv
unlik
viral
vector
preexist
immun
appear
limit
immunogen
recombin
cmv
vector
one
prototyp
vaccin
use
rhesu
cmv
vector
induc
durabl
sivspecif
effector
tcell
respons
rhesu
macaqu
provid
avirem
control
infect
mucos
inocul
vaccine
least
week
analysi
reveal
vector
stimul
uniqu
effector
tcell
respons
recogn
divers
epitop
includ
restrict
class
ii
major
histocompat
complex
molecul
significantli
breadth
tradit
vaccin
human
cmv
infect
pregnant
women
associ
birth
defect
concern
whether
strategi
made
toler
widescal
deploy
thu
strategi
yet
human
clinic
trial
one
hurdl
hiv
vaccinolog
design
immunogen
elicit
heterolog
neutral
breadth
one
approach
mosaic
vaccin
genet
materi
global
hiv
strain
comput
analyz
design
polyval
mosaic
immunogen
elicit
cellular
immun
respons
genet
divers
circul
strain
hiv
mosaic
antigen
administ
replicationincompet
vector
dna
primerecombin
vaccinia
boost
regimen
elicit
tcell
respons
enhanc
recognit
hiv
strain
divers
nonhuman
primat
anim
vaccin
admodifi
vaccinia
ankara
adad
vectorebas
vaccin
express
bival
mosaic
env
gag
pol
robust
tcell
respons
elicit
neutral
function
nonneutr
antibodi
reduct
acquisit
infect
sever
mucos
viral
challeng
earlyphas
clinic
studi
use
mosaic
vaccin
strategi
found
strong
humor
cellular
immun
respons
particularli
mosaic
prime
high
dose
boost
studi
set
stage
current
efficaci
trial
hvtn
mosaico
design
assess
regimen
adjuv
clade
c
mosaic
enrol
studi
began
clinicaltrialsgov
identifi
almost
decad
ago
nation
institut
health
vrcled
research
team
report
discoveri
broadli
neutral
antibodi
isol
person
live
previous
mention
bnab
class
neutral
isol
test
lead
launch
seri
phase
human
trial
found
infus
toler
receiv
intraven
subcutan
everi
week
importantli
particip
sera
infus
activ
vitro
viru
strain
concept
transit
antibodi
mediat
prevent
amp
studiesdphas
iib
efficaci
trial
assess
antibodymedi
prevent
led
jointli
hvtn
hiv
prevent
trial
network
one
earliest
identifi
isol
bnab
except
breadth
potenc
advanc
antibodi
isol
design
drive
new
strategi
passiv
immun
mutat
introduc
alter
amino
acid
sequenc
constant
region
heavi
chain
creat
form
exhibit
longer
halflif
serum
longer
persist
mucos
tissu
higher
bind
affin
neonat
fc
receptor
without
neg
affect
effector
function
success
evalu
phase
clinic
trial
found
well
toler
via
subcutan
intraven
rout
addit
extend
halflif
could
administ
less
frequent
make
feasibl
tool
hiv
prevent
investig
isol
sever
addit
bnab
includ
limit
multipl
antibodi
target
differ
epitop
env
like
go
need
wide
deploy
passiv
immunotherapi
program
much
like
combin
antiretrovir
therapi
requir
clinic
therapeut
success
suppress
becom
clear
singl
monoclon
antibodi
like
suffici
prevent
infect
studi
assess
safeti
pharmacokinet
profil
infus
combin
bnab
prevent
infect
clinicaltrialsgov
identifi
effect
viral
load
person
live
clinicaltrialsgov
identifi
howev
manufactur
safeti
challeng
aris
bnab
physic
combin
research
also
explor
bispecif
trispecif
antibodi
design
abil
recogn
neutral
sever
antigen
target
concurr
one
group
design
bispecif
antibodi
combin
target
site
target
apex
promis
high
potenc
neutral
breadth
virus
test
recent
trispecif
antibodi
target
site
membraneproxim
extern
region
glycan
site
engin
explor
whether
antibodi
could
effect
engag
multipl
effector
target
via
ratio
trispecif
antibodyeprotein
trispecif
antibodi
higher
breadth
potenc
neutral
approxim
virus
test
evalu
rhesu
macaqu
simian
hiv
challeng
model
anim
infus
trispecif
antibodi
protect
contrast
protect
rate
seen
alon
come
year
anticip
sever
addit
trial
antibodymedi
prevent
famili
test
concept
one
new
strategi
use
viral
vector
transfer
bnab
gene
directli
host
adenoassoci
virus
attract
candid
strategi
nonpathogen
integr
host
genom
infect
quiescent
divid
cell
recombin
adenoassoci
virus
alreadi
success
use
deliv
individu
bnab
protect
repeat
viral
mucos
challeng
human
mous
model
current
work
focus
determin
best
combin
bnab
counter
escap
mutat
preexist
resist
infecti
diseas
diphtheria
hepat
b
passiv
immunotherapi
activ
vaccin
combin
enhanc
protect
recombin
adenoassoci
virus
passiv
therapi
combin
activ
vaccin
like
becom
import
part
success
hiv
vaccin
strategi
recent
year
understand
host
immun
respons
becom
nuanc
propel
field
vaccinolog
forward
learn
manipul
host
control
bnab
induct
display
antigen
divers
obtain
neutral
breadth
key
develop
success
vaccin
one
substanti
limit
vaccin
develop
yet
clearli
defin
primari
immun
correl
protect
infect
although
sever
potenti
correl
identifi
includ
igg
antibodi
learn
thu
far
success
vaccin
candid
like
use
heterolog
primeboost
strategi
engag
humor
cellular
immun
system
provid
neutral
breadth
includ
nonneutr
protect
immun
respons
durabl
even
vaccin
may
one
piec
complex
puzzl
may
involv
combin
activ
passiv
immun
tool
author
indic
conflict
interest
regard
content
articl
